Company Profile

Biosensors International Pte Ltd(BSI) was founded in 1990, it has experienced more than 20 years of research and development, production, marketing and sales of intensive care medical products. Over the years, our company has been investing in R&D and technology to provide patients with safe and healthy products. By maintaining and operating a consistently applicable quality management system, our products could meet customers’ requirements effectively and also meet the requirements of medical device regulations in the markets we are serving.

From 1991 to 2010, our company continued to develop Thermodilution Catheter, the first generation blood pressure transducer BIOTRANS, Central Venous Catheter, the second generation pressure monitoring systems and kits BIOTRANS II, Embolectomy Catheter, Bipolar Pacing Catheter, new disposable blood pressure transducer, CVC Compound Packet, Non-latex Thermodilution Catheter, new blood pressure transducer Catrans etc., with mature technology and excellent quality, our products have achieved first-class international standards and obtained CE and FDA etc.registration certificates from more than 50 countries and regions around the world. The products are sold to Asia Pacific, Europe, America, Latin America and other countries and regions.

In 2003, Biosensors International Pte Ltd invested and established a wholly-owned subsidiary, JW ICU Medical Limited(JW ICU) in Weihai, China, which expanded China market successfully.

After spin-off from the Biosensors International Group in October 2017, Biosensors International Pte Ltd has kept on expanding the advantages of our CCP critical care business as the global sales center, will gradually build overseas sales subsidiaries, and lay a solid market foundation for new R&D products entering the market.

JW ICU Medical Limited(JW ICU was established in September 2003. It is a wholly foreign-owned company funded by Biosensors International Pte Ltd, mainly engaged in the sale of high-tech medical products for anesthesia and intensive care.

After more than ten years of development, JW ICU has matured and stabilized business operations under the technical support and management system of its parent company, Biosensors International Pte Ltd. The market operation and product sales have been deeply cultivated in China, and lasting focus on Beijing, Shanghai and Guangzhou etc. first-class regions. The business also reaches north to Heilongjiang, Jilin and Liaoning Province, west to Shanxi, Gansu and Xinjiang Provinces and south to Yunnan, Guizhou and Sichuan Province, covering 24 provinces, cities and municipalities. Sales cover almost 300 hospitals in China, including nearly 200 tertiary hospitals. CCP products are praised and highly recommended by the clinical experts, so CCP products have high reputation in domestic critical care market for quite a long time.

The company has a completed management structure, R&D team, domestic distributor system, and cooperates closely with professional product research and development institutions in China. Since 2017 the company has invested heavily in innovating technologies, developed multi-category new products and laid a solid foundation for further development of the company, which will gradually form a huge growth potential and room of development.

Milestones & Highlights

JW ICU signed IVD Project Cooperation Agreement 2018
Sterilizer got the approval from PMDA 2018
Passed audit of ENISO11135:2014 2017
Signed agreement of new Foley catheter patent transfer 2017

Vision, Mission & Core Values

Company vision: Become a strong world-class high-tech medical devices enterprise

Company philosophy: sustainable development, benefit for health

Company principles: Integrity, Pragmatism, Innovation, Collaboration

Company spirit: Development, Innovation, Practice, Pursuit of excellence

Team spirit: Loyalty & honest, harmony & cooperation, making achievements together

Quality policy: Provides high quality medical devices designed to impact the lives we touch